CAS: 57054-92-9; 5-Bromo-2-Chloro-4-Methoxypyrimidine
该化合物是一种环有火利米丁的杂交有机化合物,是一种六人组成的芳香环,含有1号阵地和3号阵地的两个氮原子. 这种特殊的化合物具有五点的溴原子,2号阵地的一个氯原子,和四点的丙酰环的甲氧组(OCH3).这些替代成分有助于其化学再活性和在各个领域的潜在应用,包括药物和农用化学.卤素(溴和氯)的存在可以加强该化合物的生物活动,影响其与生物目标的互动.甲氧基化合物还可以影响溶性与极性,使化合物适合各种合成途径.
物理性质
MSDS等安全信息
- 危险类别急性毒性 类别4(吸入)
急性毒性 类别4(经皮)
急性毒性 类别4(经口)
特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2A - 警示词Warning
- 危险描述H332 |吸入有害.
H312 |皮肤接触有害.
H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激. - 防范说明P261-P280-P305+P351+P338-
- 危险品标志Xi
- 安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
欧盟法规
C&L通报上下游产品
2,4-dichloro-5-bromopyrimidine sodium methylate 2-chloro-4-methoxy-5-phenylpyrimidine 4-methoxy-2,5-diphenylpyrimidine (5-bromo-4-methoxy-pyrimidin-2-yl)-dimethyl-amine 4-methoxypyrimidine合成工艺路线路线简述
📜5-溴-2,4-二氯嘧啶,Sodium Methylate 以 甲醇 作为反应溶剂,化学反应 12.0H,以90%的收率获得产物5-溴-2-氯-4-甲氧基嘧啶
参考文献:微波辅助,高效且区域选择性的pd催化卤代嘧啶的c-苯基化
标题:微波辅助,高效且区域选择性的pd催化卤代嘧啶的c-苯基化
摘要:我们在本文中报道,快速加热微波辐射是从相应的卤代嘧啶形成芳基嘧啶的有用工具.描述了在上述条件下,钯催化的2,4-二-和2,4,5-三卤代嘧啶与苯基硼酸的交叉偶联反应.通过使用适当的催化剂和适当的卤代嘧啶,可以在杂环的2-,4-或5-位上获得非常好的区域选择性.此外,我们表明,该方法可用于逐步制备单,二和三苯基嘧啶.
DOI:10.1016/j.Tetlet.2006.04.082
海关参考信息
- 2905110000-甲醇
2909199090-其他醚及其衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
